IMMATICS NV Share Price Today: Live Updates & Key Insights

IMMATICS NV share price today is $9.45, up -2.88%. The stock opened at $9.77 against the previous close of $9.71, with an intraday high of $9.79 and low of $9.37.

IMMATICS NV Share Price Chart

IMMATICS NV

us-stock
To Invest in {{usstockname}}
us-stock

IMMATICS NV Share Price Performance

$9.45 -0.0288(-2.88%) IMTX at 23 Mar 2026 01:39 PM Biotechnology
Lowest Today 9.37
Highest Today 9.79
Today’s Open 9.77
Prev. Close 9.71
52 Week High 12.41
52 Week Low 3.30
Day’s Range: Low 9.37 High 9.79
52-Week Range: Low 3.30 High 12.41
1 day return -
1 Week return -3.91
1 month return -4.45
3 month return -8.79
6 month return +38.21
1 year return +88.61
3 year return +33.71
5 year return -30.89
10 year return -

IMMATICS NV Institutional Holdings

T. Rowe Price Investment Management,Inc. 14.45

Baker Bros Advisors LP 9.02

RTW INVESTMENTS, LLC 8.53

Suvretta Capital Management, LLC 8.34

Perceptive Advisors LLC 7.00

Vestal Point Capital LP 4.57

T. Rowe Price Small-Cap Stock 3.92

T. Rowe Price US Small-Cap Core Equity 3.89

The Toronto-Dominion Bank 3.82

T. Rowe Price Small-Cap Value 3.50

Sofinnova Ventures 2.56

T. Rowe Price U.S. SC Value Eq Tr-D 2.21

T. Rowe Price Instl Small-Cap Stock 2.13

T. Rowe Price U.S. SC Core Eq Tr-D 1.79

Morgan Stanley - Brokerage Accounts 1.64

Citadel Advisors Llc 1.28

Wellington Management Company LLP 1.22

Jefferies Financial Group Inc 0.89

T. Rowe Price US Smlr Coms Eq A 0.79

Woodline Partners LP 0.75

Sphera Funds Management Ltd. 0.64

Alyeska Investment Group, L.P. 0.59

T. Rowe Price Associates, Inc. 0.54

Aberdeen Group PLC 0.53

University Of Texas Investment Mgmt Co 0.52

StemPoint Capital LP 0.46

Balyasny Asset Management LLC 0.44

Wasatch Ultra Growth 0.38

abrdn World Healthcare 0.36

International Biotechnology Ord 0.32

Northwestern Mutual Ser Small Cap Value 0.22

T. Rowe Price Small-Cap Value Equity 0.22

abrdn Life Sciences Investors 0.22

MEDICAL BioHealth EUR Acc 0.18

Vanguard International Explorer Inv 0.18

Wellington Intl Small Cap Research 0.17

Stt Strt®SPDR®S&PKenshoNwEcosComposETF 0.16

T. Rowe Price U.S. Equities Tr 0.15

T. Rowe Price Spectrum Mod Gr Allc 0.14

State Street® SPDR® Ptf Dev Wld exUS ETF 0.14

IMMATICS NV Market Status

Strong Buy: 6

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

IMMATICS NV Fundamentals

Market Cap 1264.53 M

PB Ratio 2.3335

PE Ratio 0.0

Enterprise Value 781.99 M

Total Assets 562.10 M

Volume 224378

IMMATICS NV Company Financials

Annual Revenue FY23:75724000 75.7M, FY22:172831000 172.8M, FY21:34763000 34.8M, FY20:31253000 31.3M, FY19:18449000 18.4M

Annual Profit FY23:null 0.0M, FY22:172831000 172.8M, FY21:34763000 34.8M, FY20:31253000 31.3M, FY19:18449000 18.4M

Annual Net worth FY23:-84078000 -84.1M, FY22:37514000 37.5M, FY21:-95061000 -95.1M, FY20:-229348000 -229.3M, FY19:-31741000 -31.7M

Quarterly Revenue Q3/2025:5187000 5.2M, Q2/2025:4737000 4.7M, Q1/2025:18582000 18.6M, Q3/2024:50559000 50.6M, Q2/2024:18755000 18.8M

Quarterly Profit Q3/2025:5187000 5.2M, Q2/2025:4737000 4.7M, Q1/2025:18582000 18.6M, Q3/2024:50559000 50.6M, Q2/2024:18660140 18.7M

Quarterly Net worth Q3/2025:-50545000 -50.5M, Q2/2025:-70348000 -70.3M, Q1/2025:-39855000 -39.9M, Q3/2024:-8570000 -8.6M, Q2/2024:-18022000 -18.0M

About IMMATICS NV & investment objective

Company Information Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Organisation Biotechnology

Employees 589

Industry Biotechnology

CEO Dr. Harpreet Singh Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

IMMATICS NV FAQs

What is the share price of IMMATICS NV today?

The current share price of IMMATICS NV is $9.45.

Can I buy IMMATICS NV shares in India?

Yes, Indian investors can buy IMMATICS NV shares by opening an international trading and demat account with Motilal Oswal.

How to buy IMMATICS NV shares in India?

You can easily invest in IMMATICS NV shares from India by:

Can I buy fractional shares of IMMATICS NV?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of IMMATICS NV?

IMMATICS NV has a market cap of $1264.53 M.

In which sector does IMMATICS NV belong?

IMMATICS NV operates in the Biotechnology sector.

What documents are required to invest in IMMATICS NV stocks?

To invest, you typically need:

What is the PE and PB ratio of IMMATICS NV?

The PE ratio of IMMATICS NV is N/A and the PB ratio is 2.33.